Clinical trial NCT00288054 (phase 1, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    study closed early due to poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven newly diagnosed single, primary, bronchogenic
             stage IIIA or selected stage IIIB (excluding malignant pleural effusion) non-small
             cell lung cancer (NSCLC) of one of the following cellular types:

               -  Adenocarcinoma

               -  Large cell carcinoma

               -  Squamous cell carcinoma

               -  Unspecified

          -  Histology or cytology from involved mediastinal or supraclavicular nodes will be
             sufficient for diagnosis if a separate primary lesion of the lung parenchyma is
             clearly evident on radiographs (i.e., a second biopsy will not be required)

          -  Underwent positron emission tomography (PET) scan within the past 42 days

               -  N2 or N3 mediastinal disease by PET scan OR enlarged nodes on CT scan determined
                  to be N2 or N3 by biopsy

          -  Measurable disease, defined as lesions that can be accurately measured in at least one
             dimension as ≥ 2 cm by conventional techniques or ≥ 1 cm by spiral CT scan

               -  Pleural effusion, ascites, bone lesions, and laboratory parameters are not
                  considered measurable disease

          -  No brain metastases

          -  Malignant pleural effusion allowed provided 1 of the following is true:

               -  Present before mediastinoscopy or exploratory thoracotomy AND the pleural fluid
                  is transudate with negative cytology

               -  Present only after but not before exploratory or staging thoracotomy AND the
                  pleural fluid is either transudate or exudate with negative cytology

               -  Present only on CT scan but not on decubitus chest x-ray AND deemed too small to
                  tap under either CT scan or ultrasound guidance

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1, meeting ≥ 1 of the following criteria OR Zubrod
             performance status 2 with no co-morbidities or meeting 1 of the following criteria:

               -  No co-morbidities

               -  FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L

               -  DLCO > 10 mL/mm Hg/min

               -  Albumin < 0.85 times lower limit of normal

               -  Unintentional weight loss > 10% within the past 6 months

               -  Controlled congestive heart failure which, in the opinion of the investigator,
                  may become decompensated due to radiotherapy

          -  FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  Must provide prior smoking history

          -  Serum bilirubin normal

          -  Meets one of the following criteria:

               -  Alkaline phosphatase (AP) ≤ 4 times ULN AND SGOT or SGPT normal

               -  AP normal AND SGOT or SGPT ≤ 2.5 times ULN

          -  No other prior malignancy within the past 5 years except adequately treated basal cell
             or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I
             or II cancer from which the patient is currently in complete remission

          -  No pregnant or nursing patients

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or curative surgery for this cancer

          -  No prior radiotherapy to the neck and/or thorax for any reason

          -  No prior therapy which specifically targets the EGFR pathway

          -  No concurrent growth factors (e.g., filgrastim [G-CSF], epoetin alfa, or
             pegfilgrastim) or amifostine

          -  No concurrent intensity-modulated radiotherapy

          -  No concurrent prophylactic mediastinal, contralateral hilar, or supraclavicular lymph
             node radiotherapy